Radicava
Manufacturing · Arizona, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
PO Box 2930, Phoenix, Arizona, 85062, Un...Phone Number
(844) 678-8978Website
www.radicava.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Radicava
Mitsubishi Tanabe Pharma America, Inc. offers RADICAVA ORS®, an oral treatment option for amyotrophic lateral sclerosis (ALS) designed to slow the loss of physical function. The product is based on years of clinical and real-world experience, and is recognized for its major contribution to patient care by the FDA. Their intended clients are patients diagnosed with ALS, caregivers, and healthcare professionals seeking effective treatment options and support resources. Additionally, the company provides various financial support options and educational materials to assist patients in understanding their treatment journey.Explore more
Popular SearchesRadicavaMitsubishi Tanabe Pharma America IncSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Radicava your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Radicava had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Radicava
Product Launch: Get notified when Radicava launches new products
Earning: See what the market has to say on Radicava recently announced quarterly report
Funding: Get notified immidiatlly once Radicava has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Radicava is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Radicava has recently received funding, and reach out quickly before it becomes old news!
Radicava, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Radicava as Masked Content
Find more new buyers
Compare Similar Companies to Radicava
Compare insights from companies similar to Radicava, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Radicava
$6.8M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Radicava is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Radicava is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Radicava.
Radicava Tech Stack
A closer look at the technologies used by Radicava
See more technologies
Radicava News & Media
Mitsubishi Tanabe Pharma America Presents New Results of RADICAVA ORS® (edaravone) from a Phase 3b Efficacy and Safety Extension Study and a Clinical Analysis of Multiple Studies at NEALS 2024
Phase 3b extension study reinforces current FDA-approved on/off regimen of RADICAVA ORS Analyses suggest improved survival in people with ALS on RADICAVA ORS compared to PRO-ACT placebo group JERSEY CITY, N.J., Oct. 21, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA)...Mitsubishi Tanabe Pharma America to Feature RADICAVA ORS® (edaravone) Real-World Data at 2024 ALS Nexus Conference
JERSEY CITY, N.J., July 9, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of four abstracts in amyotrophic lateral sclerosis (ALS) at the inaugural ALS Nexus Conference, being held in Dallas, Texas, July 14-17, 2024. The presentations...Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)
Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J., April 8, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of...RADICAVA ORS® (edaravone) Now Available in the U.S. for the Treatment of ALS
RADICAVA ORS gives people with ALS an oral treatment option that offers the same efficacy as the IV formulation of edaravone1 JERSEY CITY, N.J., June 15, 2022 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced RADICAVA ORS® (edaravone) is now available in the...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Radicava
Sign Up For FreeTo access detailed company insights
Mitsubishi Tanabe Pharma America, Inc. offers RADICAVA ORS®, an oral treatment option for amyotrophic lateral sclerosis (ALS) designed to slow the loss of physical function. The product is based on years of clinical and real-world experience, and is recognized for its major contribution to patient care by the FDA. Their intended clients are patient... Read More
